The global atrial fibrillation drugs market size was valued at USD 24.59 billion in 2024 and is projected to reach from USD ...
5hon MSN
A 240-year-old drug called digoxin could save the National Health Service (NHS) at least £100 million each year when treating ...
Discover how abelacimab reduces bleeding risks in AFib patients by effectively lowering free factor XI levels.
The atrial fibrillation (AF) device market is experiencing rapid growth, fueled by the rising prevalence of atrial fibrillation, increasing awareness of early diagnosis, and advancements in medical ...
The following is a summary of “Cost-effectiveness of digoxin versus beta blockers in permanent atrial fibrillation: the Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) ...
Researchers have found in a new research that among patients with atrial fibrillation who are at moderate-to-high risk for ...
A new treatment at Unity Point Health is offering promising results for those with irregular heartbeats, otherwise known as ...
DelveInsight, a leader in pharma consulting services, conducted an Asset Prioritization Analysis for a pharmaceutical client ...
Recent research shows the incredible success of radiofrequency ablation in treating AFib, offering renewed hope for patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback